What is the current valuation of the Tuberculosis Therapeutics Market as of 2024?

The Tuberculosis Therapeutics Market was valued at 1.731 USD Billion in 2024. Read More

What is the projected market size for the Tuberculosis Therapeutics Market by 2035?

The market is projected to reach 4.721 USD Billion by 2035. Read More

What is the expected CAGR for the Tuberculosis Therapeutics Market during the forecast period 2025 - 2035?

The expected CAGR for the Tuberculosis Therapeutics Market during 2025 - 2035 is 9.55%. Read More

Which companies are the key players in the Tuberculosis Therapeutics Market?

Key players include Johnson & Johnson, Roche, Sanofi, GlaxoSmithKline, Novartis, Merck & Co., AstraZeneca, AbbVie, and Pfizer. Read More

What was the valuation of First-Line Therapies in 2024?

First-Line Therapies were valued at 0.693 USD Billion in 2024. Read More

What is the projected valuation for Rifamycins by 2035?

Rifamycins are projected to reach a valuation of 1.6 USD Billion by 2035. Read More

What are the routes of administration for tuberculosis therapeutics?

Routes of administration include Oral, Injectable, and Intravenous. Read More

What is the expected market performance for multidrug-resistant therapies by 2035?

Multidrug-Resistant Therapies are projected to reach a valuation of 1.899 USD Billion by 2035. Read More

Tuberculosis Therapeutics Market

Q: What are the market segments based on treatment type in the Tuberculosis Therapeutics Market?

The market segments include First-Line Therapies, Second-Line Therapies, Multidrug-Resistant Therapies, and Extensively Drug-Resistant Therapies. Read More

Q: How is the Tuberculosis Therapeutics Market segmented by drug class?

The market is segmented into Quinolones, Rifamycins, Nitroimidazoles, Macrolides, and Aminoglycosides. Read More

ID: MRFR/HC/39276-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Tuberculosis Therapeutics Market Research Report: Size, Share, Trend Analysis By Treatment Type (First-Line Therapies, Second-Line Therapies, Multidrug-Resistant Therapies, Extensively Drug-Resistant Therapies), By Drug Class (Quinolones, Rifamycins, Nitroimidazoles, Macrolides, Aminoglycosides), By Route of Administration (Oral, Injectable, Intravenous), By Patient Population (Adults, Children, Pregnant Women), By Tuberculosis Type (Pulmonary, Extra-Pulmonary, Multidrug-Resistant) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Tuberculosis Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Billion)
  1. 4.1.1 First-Line Therapies
  2. 4.1.2 Second-Line Therapies
  3. 4.1.3 Multidrug-Resistant Therapies
  4. 4.1.4 Extensively Drug-Resistant Therapies
2. 4.2 Healthcare, BY Drug Class (USD Billion)
  1. 4.2.1 Quinolones
  2. 4.2.2 Rifamycins
  3. 4.2.3 Nitroimidazoles
  4. 4.2.4 Macrolides
  5. 4.2.5 Aminoglycosides
3. 4.3 Healthcare, BY Route of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Injectable
  3. 4.3.3 Intravenous
4. 4.4 Healthcare, BY Patient Population (USD Billion)
  1. 4.4.1 Adults
  2. 4.4.2 Children
  3. 4.4.3 Pregnant Women
5. 4.5 Healthcare, BY Tuberculosis Type (USD Billion)
  1. 4.5.1 Pulmonary
  2. 4.5.2 Extra-Pulmonary
  3. 4.5.3 Multidrug-Resistant
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GlaxoSmithKline (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY DRUG CLASS
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 US MARKET ANALYSIS BY PATIENT POPULATION
7. 6.7 US MARKET ANALYSIS BY TUBERCULOSIS TYPE
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY DRUG CLASS
10. 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
11. 6.11 CANADA MARKET ANALYSIS BY PATIENT POPULATION
12. 6.12 CANADA MARKET ANALYSIS BY TUBERCULOSIS TYPE
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY DRUG CLASS
16. 6.16 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
17. 6.17 GERMANY MARKET ANALYSIS BY PATIENT POPULATION
18. 6.18 GERMANY MARKET ANALYSIS BY TUBERCULOSIS TYPE
19. 6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
20. 6.20 UK MARKET ANALYSIS BY DRUG CLASS
21. 6.21 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
22. 6.22 UK MARKET ANALYSIS BY PATIENT POPULATION
23. 6.23 UK MARKET ANALYSIS BY TUBERCULOSIS TYPE
24. 6.24 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY DRUG CLASS
26. 6.26 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
27. 6.27 FRANCE MARKET ANALYSIS BY PATIENT POPULATION
28. 6.28 FRANCE MARKET ANALYSIS BY TUBERCULOSIS TYPE
29. 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY DRUG CLASS
31. 6.31 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
32. 6.32 RUSSIA MARKET ANALYSIS BY PATIENT POPULATION
33. 6.33 RUSSIA MARKET ANALYSIS BY TUBERCULOSIS TYPE
34. 6.34 ITALY MARKET ANALYSIS BY TREATMENT TYPE
35. 6.35 ITALY MARKET ANALYSIS BY DRUG CLASS
36. 6.36 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
37. 6.37 ITALY MARKET ANALYSIS BY PATIENT POPULATION
38. 6.38 ITALY MARKET ANALYSIS BY TUBERCULOSIS TYPE
39. 6.39 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY DRUG CLASS
41. 6.41 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
42. 6.42 SPAIN MARKET ANALYSIS BY PATIENT POPULATION
43. 6.43 SPAIN MARKET ANALYSIS BY TUBERCULOSIS TYPE
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY PATIENT POPULATION
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY TUBERCULOSIS TYPE
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 CHINA MARKET ANALYSIS BY DRUG CLASS
52. 6.52 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
53. 6.53 CHINA MARKET ANALYSIS BY PATIENT POPULATION
54. 6.54 CHINA MARKET ANALYSIS BY TUBERCULOSIS TYPE
55. 6.55 INDIA MARKET ANALYSIS BY TREATMENT TYPE
56. 6.56 INDIA MARKET ANALYSIS BY DRUG CLASS
57. 6.57 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
58. 6.58 INDIA MARKET ANALYSIS BY PATIENT POPULATION
59. 6.59 INDIA MARKET ANALYSIS BY TUBERCULOSIS TYPE
60. 6.60 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY DRUG CLASS
62. 6.62 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
63. 6.63 JAPAN MARKET ANALYSIS BY PATIENT POPULATION
64. 6.64 JAPAN MARKET ANALYSIS BY TUBERCULOSIS TYPE
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY PATIENT POPULATION
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY TUBERCULOSIS TYPE
70. 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
72. 6.72 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
73. 6.73 MALAYSIA MARKET ANALYSIS BY PATIENT POPULATION
74. 6.74 MALAYSIA MARKET ANALYSIS BY TUBERCULOSIS TYPE
75. 6.75 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY DRUG CLASS
77. 6.77 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
78. 6.78 THAILAND MARKET ANALYSIS BY PATIENT POPULATION
79. 6.79 THAILAND MARKET ANALYSIS BY TUBERCULOSIS TYPE
80. 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY DRUG CLASS
82. 6.82 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
83. 6.83 INDONESIA MARKET ANALYSIS BY PATIENT POPULATION
84. 6.84 INDONESIA MARKET ANALYSIS BY TUBERCULOSIS TYPE
85. 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
87. 6.87 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
88. 6.88 REST OF APAC MARKET ANALYSIS BY PATIENT POPULATION
89. 6.89 REST OF APAC MARKET ANALYSIS BY TUBERCULOSIS TYPE
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY DRUG CLASS
93. 6.93 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
94. 6.94 BRAZIL MARKET ANALYSIS BY PATIENT POPULATION
95. 6.95 BRAZIL MARKET ANALYSIS BY TUBERCULOSIS TYPE
96. 6.96 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY DRUG CLASS
98. 6.98 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
99. 6.99 MEXICO MARKET ANALYSIS BY PATIENT POPULATION
100. 6.100 MEXICO MARKET ANALYSIS BY TUBERCULOSIS TYPE
101. 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
103. 6.103 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
104. 6.104 ARGENTINA MARKET ANALYSIS BY PATIENT POPULATION
105. 6.105 ARGENTINA MARKET ANALYSIS BY TUBERCULOSIS TYPE
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT POPULATION
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TUBERCULOSIS TYPE
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY PATIENT POPULATION
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TUBERCULOSIS TYPE
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY PATIENT POPULATION
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TUBERCULOSIS TYPE
122. 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
124. 6.124 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
125. 6.125 REST OF MEA MARKET ANALYSIS BY PATIENT POPULATION
126. 6.126 REST OF MEA MARKET ANALYSIS BY TUBERCULOSIS TYPE
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY PATIENT POPULATION, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY PATIENT POPULATION, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY TUBERCULOSIS TYPE, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY TUBERCULOSIS TYPE, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.2.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.3.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.4.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.5.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.6.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.7.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.8.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.9.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.10.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.11.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.12.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.13.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.14.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.15.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.16.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.17.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.18.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.19.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.20.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.21.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.22.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.23.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.24.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.25.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.26.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.27.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.28.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.29.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
  5. 7.30.5 BY TUBERCULOSIS TYPE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Treatment Type (USD Billion, 2025-2035)

First-Line Therapies
Second-Line Therapies
Multidrug-Resistant Therapies
Extensively Drug-Resistant Therapies

Healthcare By Drug Class (USD Billion, 2025-2035)

Quinolones
Rifamycins
Nitroimidazoles
Macrolides
Aminoglycosides

Healthcare By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Intravenous

Healthcare By Patient Population (USD Billion, 2025-2035)

Adults
Children
Pregnant Women

Healthcare By Tuberculosis Type (USD Billion, 2025-2035)

Pulmonary
Extra-Pulmonary
Multidrug-Resistant

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”